How to Tell the Difference Between MPS I and JIA

Although attenuated Mucopolysaccharidosis type I (MPS I) and Juvenile Idiopathic Arthritis (JIA) both cause stiff, contracted joints in children, they are fundamentally different diseases. JIA is an inflammatory condition that causes “hot,” swollen joints, while MPS I is a metabolic condition that causes “cold,” mechanically restricted joints without obvious inflammation ^[1][1]. Because their joint symptoms can look similar at first glance, children with attenuated MPS I (like Scheie syndrome) are very frequently misdiagnosed with JIA. Telling the difference requires looking at how the joints feel, how they respond to standard arthritis treatments, and whether other non-joint symptoms are present ^[1][2].

“Hot” vs. “Cold” Joints

In JIA, the child’s immune system attacks the joint lining, leading to active inflammation. The joints often feel warm to the touch, appear red or swollen, and can be quite painful. Blood tests typically show elevated inflammatory markers, such as ESR (erythrocyte sedimentation rate) or CRP (C-reactive protein).

In contrast, the joint stiffness in MPS I is caused by the progressive buildup of complex sugar molecules called glycosaminoglycans (GAGs) in the tendons, ligaments, and joint capsules ^[3][2]. These joints are “cold”—they are stiff, tight, and mechanically restricted, but they usually lack redness, heat, or soft-tissue swelling ^[1]. While they can become achy over time from restricted movement, they often lack the acute, inflammatory pain typical of JIA ^[1]. Blood tests for inflammation (ESR and CRP) in a child with MPS I are usually completely normal ^[1].

Quick Comparison: JIA vs. MPS I

Response to Treatment

Another major clue that a child might have MPS I instead of JIA is how they respond (or fail to respond) to standard arthritis treatments ^[1].

• Medications: JIA typically responds to anti-inflammatory medications (NSAIDs like ibuprofen) or biologic drugs that calm the immune system. In MPS I, these medications do not improve joint mobility because they do not clear the underlying GAG buildup ^[4][2].
• Physical Therapy: While physical therapy is important for both conditions, it often helps “loosen up” JIA joints significantly. In MPS I, the joint contractures (permanent tightening of the tissues) are fixed and mechanically restricted. Physical therapy may prevent further worsening but will not restore a normal range of motion ^[5][1].

Unique Red Flags for MPS I

If a child diagnosed with JIA has any of the following features, it should raise immediate suspicion for a metabolic disorder like MPS I and prompt further testing:

• Carpal Tunnel Syndrome: This is extremely rare in typical childhood arthritis but is a very frequent and early sign of MPS I ^[6][7].
• Claw Hand Deformity: A specific curling of the fingers that does not fluctuate from day to day ^[5][1].
• Bone Changes: Early standard X-rays in attenuated MPS I may appear unremarkable or show specific irregular bone shapes called dysostosis multiplex ^[1][5]. This sounds intimidating, but it is simply the medical term doctors use to describe the characteristic pattern of thickened or abnormally shaped bones seen on X-rays in metabolic disorders.
• Other Physical Signs: Unlike JIA, MPS I affects many other parts of the body. Look for non-joint clues like a history of umbilical or inguinal hernias, frequent ear or sinus infections, or heart valve abnormalities ^[1][8]. Another sign is corneal clouding (an opacity in the clear front part of the eye); early on, this usually cannot be seen with the naked eye and requires an eye doctor to look with a special microscope called a slit lamp ^[1].

Next Steps if You Suspect MPS I

Approaching a specialist to ask if they misdiagnosed your child can feel intimidating. You can frame it as wanting to rule out other possibilities: “Given that her inflammatory markers are normal and the NSAIDs aren’t helping, could we look into metabolic causes like MPS I?”

If your child’s “arthritis” doesn’t fit the typical JIA pattern, it is completely reasonable to ask for more investigation. A simple urine test measuring uGAG (urinary glycosaminoglycan) levels can act as a screening tool ^[1]. If the screen is positive, a blood test checking for the specific enzyme that is deficient in MPS I (alpha-L-iduronidase), or a genetic test looking at the IDUA gene, is needed to officially confirm the diagnosis ^[1]. Early and correct diagnosis is critical because metabolic treatments, such as enzyme replacement therapy (ERT), can slow or prevent severe, permanent joint and tissue damage ^[9][10].